Enteric-coated mycophenolate sodium: Tolerability profile compared with mycophenolate mofetil

Drugs

Volumn 65, Issue 8, 2005, Pages 1037-1050

  Behrend, Matthias ^a   Braun, Felix ^b  

^a Klinikum Deggendorf   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTACID AGENT; CALCINEURIN INHIBITOR; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; FERROUS SULFATE; GANCICLOVIR; LIVE VACCINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCARBOPHIL CALCIUM; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RAPAMYCIN; TACROLIMUS;

ABDOMINAL PAIN; ALOPECIA; AREA UNDER THE CURVE; BIOEQUIVALENCE; CELL PROLIFERATION; CLINICAL TRIAL; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENTERIC COATED TABLET; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GRAFT REJECTION; HEMATOLOGIC DISEASE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTESTINE CELL; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NAUSEA; NEUTROPENIA; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PNEUMONIA; REVIEW; SEPSIS; UPPER GASTROINTESTINAL TRACT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING;

BIOLOGICAL AVAILABILITY; HUMANS; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED;

EID: 20544469447     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565080-00001     Document Type: Review

References (104)

1. Srinivas TR, Kaplan B, Meier-Kriesche HU. Mycophenolate mofetil in solid-organ transplantation. Expert Opin Pharmacother 2003; 4 (12): 2325-45
2. Placebo-controlled study of mycophenolate mofetil combined with cydosporin and corticosteroids for prevention of acute rejection: European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345 (8961): 1321-5
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation: the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61 (7): 1029-37
4. Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56 (1): 75-82
5. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients: US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60 (3): 225-32
6. Taylor DO, Ensley RD, Olsen SL, et al. Mycophenolate mofetil (RS-61443): preclinical, clinical, and three-year experience in heart transplantation. J Heart Lung Transplant 1994; 13 (4): 571-82
7. Danovitch GM. Immunosuppressant-induced metabolic toxicities. Transplant Rev 2000; 14 (2): 65-81
8. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000; 35 (2): 333-46
9. Takemoto SK. Patterns and outcome for maintenance immunosuppression in the UNOS renal transplant registry. Transplant Proc 2002; 34 (5): 1632-4
10. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17 (3): 200-5
11. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004; 5 (6): 1333-45
12. Gabardi S, Tran JL, Clarkson MR. Enteric-coated mycophenolate sodium. Ann Pharmacother 2003; 37 (11): 1685-93
13. Baker DE. Bioequivalence of azathioprine products. Rev Gastroenterol Disord 2003; 3 (4): 219-23
14. Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA 1987; 258 (9): 1200-4
15. Alloway RR, Isaacs R, Lake K, et al. Report of the American conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 2003; 3(10): 1211-5
16. Galbraith CA, Hathaway D. Long-term effects of transplantation on quality of life. Transplantation 2004; 77 Suppl. 9: S84-7
17. Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47 (2-3): 215-45
18. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47 (2-3): 85-118
19. Carr SF, Papp E, Wu JC, et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268 (36): 27286-90
20. Natsumeda Y, Ohno S, Kawasaki H, et al. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990; 265 (9): 5292-5
21. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136: 5-28
22. Bardsley-Elliot A, Noble S, Foster RH. Mycophenolate mofetil. Biodrugs 1999; 12 (5): 363-410
23. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24 (9): 645-63
24. Ransom JT. Mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995; 17 (6): 681-4
25. Novartis Transplantation & Immunology. Myfortic Produktmonographie. Nürnberg: Novartis Pharma GmbH, 2004: 1-40
26. Simmons WD, Rayhill SC, Sollinger HW. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf 1997; 17 (2): 75-92
27. Schmouder R, Arns W, Merkel F, et al. Pharmacokinetics of ERL080A: a new enteric coated formulation of mycophenolic acid-sodium [abstract]. Transplantation 1999 Apr 15; 67 (7): S203
28. Budde K, Glander P, Hahn U, et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance renal transplant patients [abstract]. Am J Transplant 2002; 2 Suppl. 3: 399
29. Arns W, Schmouder R, Choi L, et al. Absorption of enteric coated mycophenolate sodium (EC-MPS) is proprotional over a wide dose range [poster no. 672]. 10th Congress of the European Society for Organ Transplantation; 2001 Oct 6-11; Lisbon, 162
30. Granger DK. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant Proc 2001; 33 (7-8): 3241-4
31. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34 (6): 429-55
32. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996; 28 (2): 925-9
33. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999; 126 (5): 1075-82
34. Griesmacher A, Weigel G, Seebacher G, et al. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide. Clin Chem 1997; 43 (12): 2312-7
35. Shipkova M, Schutz E, Armstrong VW, et al. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit. Clin Chem 2000; 46 (3): 365-72
36. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998; 65 (8): 1127-9
37. Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000; 22(1): 27-30
38. Behrend M. Mycophenolate mofetil: suggested guidelines for use in kidney transplantation. Biodrugs 2001; 15 (1): 37-53
39. Fulton B, Markham A. Mycophenolate mofetil: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51 (2): 278-98
40. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000; 22 (1): 14-9
41. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001; 34 (1): 17-22
42. Morii M, Ueno K, Ogawa A, et al. Impairment of mycophenolate mofetil absorption by iron ion. Clin Pharmacol Ther 2000; 68 (6): 613-6
43. Kato R, Ooi K, Ikura-Mori M, et al. Impairment of mycophenolate mofetil absorption by calcium polycarbophil. J Clin Pharmacol 2002; 42 (11): 1275-80
44. Schmidt LE, Rasmussen A, Norrelykke MR, et al. The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. Liver Transpl 2001; 7 (8): 739-42
45. Anaizi N. Drug interactions involving immunosuppressive agents. Graft 2001; 4 (4): 232-47
46. Shipkova M, Armstrong VW, Kuypers D, et al. Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report. Ther Drug Monit 2001; 23 (6): 717-21
47. Smak Gregoor PJ, van Gelder T, Hesse CJ, et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant 1999; 14 (3): 706-8
48. Zucker K, Tsaroucha A, Olson L, et al. Evidence that tacrolimus augments the bioavailability of mycophenalate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999; 21 (1): 35-43
49. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001; 23 (2): 119-28
50. Flechner SM, Zhou L, Derweesh I, et al. The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients. Transplantation 2003; 76 (12): 1729-34
51. Cattaneo D, Perico N, Gaspari F, et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 2002; 62 (3): 1060-7
52. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998; 44 (7): 1481-8
53. Shipkova M, Schutz E, Armstrong VW, et al. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 1999; 31 (1-2): 1135-7
54. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25 (2): 137-57
55. Mourad M, Wallemacq P, Konig J, et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet 2002; 41 (5): 319-27
56. Shaw LM, Nawrocki A, Korecka M, et al. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit 2004; 26 (4): 347-51
57. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000; 22 (1): 20-6
58. Jain A, Venkataramanan R, Hamad IS, et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001; 41 (3): 268-76
59. Schuurman HJ, Pally C, Fringeli-Tanner M, et al. Comparative efficacy of mycophenolate sodium (MPS) and mycophenolate mofetil (MMF) with and without cyclosporine in rat transplantation models. Transplantation 2001; 72 (11): 1776-83
60. Chanda SM, Sellin JH, Torres CM, et al. Comparative gastrointestinal effects of mycophenolate mofetil capsules and entericcoated tablets of sodium-mycophenolic acid in beagle dogs. Transplant Proc 2002; 34 (8): 3387-92
61. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4 (2): 237-43
62. Salvadori M, Holzer H, de Mattos A, et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4 (2): 231-6
63. Nashan B, Ivens K, Suwelack B, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Transplant Proc 2004; 36 Suppl. 2: 521S-3S
64. Abbud-Filho M, Giron F, Hernandez E, et al. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study. Transplant Proc 2004; 36 (6): 1647-9
65. Chapman JR. Compliance: the patient, the doctor, and the medication? Transplantation 2004; 77 (5): 782-6
66. Nickels MW. Common psychiatric problems in the well transplant patient. Graft 2001; 4: 290-8
67. Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation 2000; 70 (5): 711-6
68. Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry 2000; 22 (6): 412-24
69. Swanson MA, Palmeri D, Vossler ED, et al. Noncompliance in organ transplant recipients. Pharmacotherapy 1991; 11 (6): 173S-4S
70. Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77 (5): 769-76
71. Schweizer RT, Rovelli M, Palmeri D, et al. Noncompliance in organ transplant recipients. Transplantation 1990; 49 (2): 374-7
72. Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998; 66 (12): 1718-26
73. De Geest S, Borgerraans L, Gemoets H, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59 (3): 340-7
74. Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4 (9): 1509-13
75. Chisholm MA, Vollenweider LJ, Mulloy LL, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation 2000; 70 (8): 1240-4
76. Siegal B, Greenstein S. Compliance and noncompliance in kidney transplant patients: cues for transplant coordinators. J Transpl Coord 1999; 9 (2): 104-8
77. Nevins TE, Kruse L, Skeans MA, et al. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001; 60 (4): 1565-70
78. Hilbrands LB, Hoitsma AJ, Koene RA. Medication compliance after renal transplantation. Transplantation 1995; 60 (9): 914-20
79. De Geest S, Abraham I, Moons P, et al. Late acute rejection and subclinical noncompliance with cyclosporine therapy in heart transplant recipients. J Heart Lung Transplant 1998; 17 (9): 854-63
80. Jindel RM, Joseph JT, Morris MC, et al. Noncompliance after kidney transplantation: a systematic review. Transplant Proc 2003; 35 (8): 2868-72
81. Lo A, Alloway RR. Strategies to reduce toxicities and improve outcomes in renal transplant recipients. Pharmacotherapy 2002; 22 (3): 316-28
82. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation. Am J Manag Care 2003; 9 (2): 155-71
83. Rianthavorn P, Ettenger RB, Malekzadeh M, et al. Noncompliance with immunosuppressive medications in pediatric and adolescent patients receiving solid-organ transplants. Transplantation 2004; 77 (5): 778-82
84. Shemesh E, Shneider BL, Savitzky JK, et al. Medication adherence in pediatric and adolescent liver transplant recipients. Pediatrics 2004; 113(4): 825-32
85. Papalois VE, Moss A, Gillingham KJ, et al. Pre-emptive transplants for patients with renal failure: an argument against waiting until dialysis. Transplantation 2000; 70 (4): 625-31
86. Stoves J, Newstead CG. Variability of cyclosporine exposure and its relevance to chronic allograft nephropathy: a case-control study. Transplantation 2002; 74 (12): 1794-7
87. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14 (9): 2381-6
88. Sollinger H. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients. Transplant Proc 2004; 36 Suppl. 2: 517S-20S
89. Helderman JH, Goral S. Gastrointestinal complications of transplant immunosuppression. J Am Soc Nephrol 2002; 13 (1): 277-87
90. Rubin RH. Gastrointestinal infectious disease complications following transplantation and their differentiation from immunosuppressant-induced gastrointestinal toxicities. Clin Transplant 2001; 15 Suppl. 4: 11-22
91. Pescovitz MD, Navarro MT. Immunosuppressive therapy and post-transplantation diarrhea. Clin Transplant 2001; 15 Suppl. 4: 23-8
92. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients: mycophenolate mofetil investigators. Transplantation 1998; 66 (4): 507-15
93. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7 (5): 442-50
94. Maes BD, Dalle I, Geboes K, et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75 (5): 665-72
95. Skelly MM, Logan RF, Jenkins D, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease. Inflamm Bowel Dis 2002; 8 (2): 93-7
96. Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 2003; 11 (4): 295-302
97. Schutz E, Shipkova M, Armstrong VW, et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999; 45 (3): 419-22
98. Wieland E, Shipkova M, Schütz E, et al. The acyl glucuronide of the immunosuppressant mycophenolic acid induces release of proinflammatory cytokines and TNF-alpha mRNA expression [abstract]. Clin Chem 1999; 45 Suppl. 6: A127
99. Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000; 33 (2): 107-13
100. Spahn-Langguth H, Benet LZ. Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 1992; 24 (1): 5-47
101. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356 (9225): 194-202
102. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69 (7): 1252-60
103. Miller J, Mendez R, Pirsch JD, et al. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients: FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000; 69 (5): 875-80
104. Bjarnason I. Enteric coating of mycophenolate sodium: a rational approach to limit topical gastrointestinal lesions and extend the therapeutic index of mycophenolate. Transplant Proc 2001; 33 (7-8): 3238-40